STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

CRNX CRINETICS PHARMACEUTICALS INCORPORATED StockScouter® Report

2

StockScouter® Score

CRINETICS PHARMACEUTICALS INCORPORATED, a mid cap company in the healthcare sector, is expected to underperform the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • One or more less experienced analysts has modestly increased quarterly earnings estimates for CRNX. Positive/Neutral

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • Moving average analysis for CRNX suggests weak price movement over the medium term. Negative
  • Earnings growth in the past year has decelerated moderately compared to earnings growth in the past three years. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be neutral, stocks will be , and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 60% done.
Progress: 20% done.
Low
High

Core Model Grades

C
D
F
F

Previous Ratings

2
3
4